Technical Trend Overview
As of 6 Feb 2026, Anuh Pharma Ltd’s share price closed at ₹80.22, down 2.05% from the previous close of ₹81.90. The stock’s 52-week high stands at ₹115.00, while the low is ₹68.00, indicating a wide trading range over the past year. The recent price action and technical parameters suggest a shift towards a bearish momentum, with the overall technical trend changing from mildly bearish to bearish.
The daily moving averages currently indicate a mildly bearish outlook, with the stock trading below key short-term averages. This suggests that the immediate price momentum is weakening, and the bears are gaining control. The weekly and monthly technical indicators reinforce this view, signalling caution for investors.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) remains bearish on both weekly and monthly timeframes. The MACD line continues to stay below the signal line, confirming sustained downward momentum. This persistent bearish MACD reading implies that the stock is likely to face continued selling pressure in the near term.
Meanwhile, the Know Sure Thing (KST) indicator also aligns with this bearish narrative, showing bearish signals on both weekly and monthly charts. The KST’s negative momentum corroborates the MACD’s outlook, suggesting that the stock’s price momentum is weakening across multiple time horizons.
RSI and Bollinger Bands Analysis
The Relative Strength Index (RSI) on weekly and monthly charts currently shows no clear signal, hovering in a neutral zone. This indicates that while the stock is not yet oversold, it lacks the bullish momentum needed to reverse the downtrend. Investors should watch for any RSI movement below 30, which could signal an oversold condition and potential for a rebound.
Bollinger Bands on the weekly timeframe are moving sideways, reflecting a period of consolidation and indecision among traders. However, on the monthly scale, the bands show a mildly bearish bias, with the price trending closer to the lower band. This suggests that volatility may increase on the downside if selling intensifies.
Volume and Dow Theory Signals
On-Balance Volume (OBV) readings are mildly bearish on both weekly and monthly charts, indicating that volume trends are supporting the price decline. This volume behaviour suggests that selling pressure is accompanied by increased trading activity, which often precedes further price weakness.
Dow Theory assessments provide a mixed picture: weekly signals are mildly bearish, while monthly signals show no clear trend. This divergence implies that while short-term technicals are deteriorating, the longer-term trend remains uncertain, warranting close monitoring.
Perfect timing to enter! This Small Cap from IT - Software just turned profitable with growth momentum clearly building up. Get in before the broader market notices!
- - New profitability achieved
- - Growth momentum building
- - Under-the-radar entry
Comparative Performance and Market Context
When compared with the broader Sensex index, Anuh Pharma’s returns present a mixed picture. Over the past week, the stock outperformed the Sensex with an 8.46% gain versus the index’s 0.91%. However, this short-term strength contrasts with longer-term underperformance. Year-to-date, the stock has declined marginally by 0.32%, while the Sensex fell 2.24%. Over the past year, Anuh Pharma’s return is down 19.17%, significantly lagging the Sensex’s 6.44% gain.
Longer-term returns show some resilience, with the stock delivering an 80.98% gain over three years, outperforming the Sensex’s 36.94%. Yet, over five and ten years, the stock has underperformed the benchmark, returning 23.89% and 10.65% respectively, compared to the Sensex’s 64.22% and 238.44%. This disparity highlights the stock’s volatile nature and sector-specific challenges.
Mojo Score and Analyst Ratings
Anuh Pharma currently holds a Mojo Score of 31.0, categorised as a Sell rating. This represents a downgrade from a previous Strong Sell grade on 4 Feb 2026, reflecting a slight improvement but still signalling caution. The company’s Market Cap Grade is 4, indicating a relatively small market capitalisation which may contribute to higher volatility and liquidity risks.
The downgrade in technical trend from mildly bearish to bearish aligns with the Mojo Grade adjustment, underscoring the deteriorating technical outlook. Investors should weigh these signals carefully against fundamental factors before making investment decisions.
Considering Anuh Pharma Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Investor Takeaways and Outlook
Technical indicators for Anuh Pharma Ltd suggest a cautious stance for investors. The bearish MACD and KST readings, combined with mildly bearish moving averages and volume trends, point to a continuation of downward momentum in the near term. The lack of a clear RSI signal means the stock is not yet oversold, so further declines cannot be ruled out.
Given the stock’s recent underperformance relative to the Sensex and its downgrade in Mojo Grade, investors should consider risk management strategies. Those with existing positions may want to monitor for signs of technical reversal or stabilisation before adding exposure. New investors might prefer to explore alternative opportunities within the Pharmaceuticals & Biotechnology sector that demonstrate stronger technical and fundamental profiles.
In summary, while Anuh Pharma Ltd has shown pockets of short-term strength, the prevailing technical momentum is bearish. The stock’s performance will likely remain sensitive to sector dynamics and broader market conditions, necessitating close observation of key technical levels and volume patterns.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
